Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,186.95
+2.5%		$1,173.51
$783.85
▼
$1,292.65
$1.09T0.462.23 million shs2.30 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.20
+1.8%		$43.86
$35.12
▼
$64.16
$167.57B0.7614.85 million shs13.59 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.08%-2.30%+0.92%-5.02%+36.93%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.15%-2.15%-19.53%-23.27%-37.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,186.95
+2.5%		$1,173.51
$783.85
▼
$1,292.65
$1.09T0.462.23 million shs2.30 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.20
+1.8%		$43.86
$35.12
▼
$64.16
$167.57B0.7614.85 million shs13.59 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.08%-2.30%+0.92%-5.02%+36.93%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.15%-2.15%-19.53%-23.27%-37.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,312.3610.57% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.07
Hold$102.85169.22% Upside

Current Analyst Ratings Breakdown

Latest LLY and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,419.00 ➝ $1,430.00
10/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
9/28/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,400.00 ➝ $1,500.00
9/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$1,250.00
9/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cfra logo
Cfra
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell$38.00
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B17.14$25.78 per share46.05$28.07 per share42.29
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.65$4.77 per share8.01$6.58 per share5.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8039.8325.441.4233.53%97.83%23.23%10/29/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.099.3411.201.2335.36%58.61%20.91%11/4/2026 (Estimated)

Latest LLY and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.7590N/AN/AN/A$11.12 billionN/A
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$9.92N/AN/AN/A$22.32 billionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.58%+15.18%23.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.822.15%+21.74%20.05%N/A

Latest LLY and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk's Liver-Fat Win Meets a Street Waiting for November Proof
 |  ad-hoc-news.deA
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-nvo-increases-despite-204505225.html
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
 |  zacks.comhttps://www.zacks.com/stock/news/3002183/novo-nordisk-nvo-increases-despite-market-slip-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-3002183
Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
October 7 at 12:19 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-130956416.html
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
October 7 at 11:06 AM  |  zacks.comhttps://www.zacks.com/stock/news/3001796/can-nvo-s-semaglutide-push-create-growth-beyond-cardiometabolic-care?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-3001796
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
October 6 at 8:15 PM  |  fool.comhttps://www.fool.com/investing/2026/10/06/novo-stock-is-down-more-than-70-from-its-peak-valu/
Novo Nordisk's Oral Wegovy Data Land as CFRA Turns Bearish on the Stock
October 6 at 3:35 PM  |  ad-hoc-news.deA
Novo Nordisk (NVO): Pipeline Timing Matters as GLP-1 Competition Intensifies
October 6 at 3:35 PM  |  news.alphastreet.comN
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
October 6 at 10:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/3000789/is-most-watched-stock-novo-nordisk-a-s-nvo-worth-betting-on-now?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks-3000789
FDA extends denecimig review: Novo Nordisk stock loses 1.02 percent
October 6 at 8:53 AM  |  ad-hoc-news.deA
Novo Nordisk A/S $NVO Stock Sold by Eastern Bank
October 6 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novo-nordisk-as-nvo-stock-sold-by-eastern-bank-2026-10-06/
Novo Looks Beyond GLP-1s as Competition Intensifies
October 5 at 1:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-looks-beyond-glp-1s-125437665.html
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
October 5 at 1:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cn-bio-announces-expert-speaker-161200005.html
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
October 5 at 1:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/type-2-diabetes-market-grow-170000037.html
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
October 5 at 12:41 PM  |  zacks.comhttps://www.zacks.com/stock/news/3000274/novo-s-denecimig-bla-review-delayed-by-fda-facility-remediation-work?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3000274
Novo Looks Beyond GLP-1s as Competition Intensifies
October 5 at 9:51 AM  |  insidermonkey.comhttps://www.insidermonkey.com/news/novo-looks-beyond-glp-1s-as-competition-intensifies-1844257/
Novo Nordisk Balances Pipeline Bets and US Restructuring as Shares Languish 25% Below Year-Start Levels
October 5 at 8:52 AM  |  ad-hoc-news.deA
FDA extends denecimig review: what it means for Novo Nordisk stock
October 5 at 8:52 AM  |  ad-hoc-news.deA
FDA Extends Review of Novo Nordisk Haemophilia A Treatment Denecimig
October 5 at 8:52 AM  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/37434/fda-extends-review-of-novo-nordisk-haemophilia-a-treatment-denecimig
Novo Nordisk A/S – Share repurchase programme
October 5 at 8:52 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-share-repurchase-programme-123200929.html
Novo Nordisk Licenses Chinese Oral Obesity Candidate as Heart-Data Edge and FDA Setback Define a Busy Fortnight
October 4 at 7:02 PM  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Woman wearing an Oura ring holds a coffee cup at an outdoor table with a city skyline behind her.
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
By Jeffrey Neal Johnson | September 22, 2026
Three-panel composite showing a laboratory workbench, an open-plan office with desks, and a pharmacy with stocked medicine shelves.
3 Healthcare Stocks for 3 Stages of Life
By Jessica Mitacek | September 15, 2026
Novo Nordisk logo displayed in a laboratory setting with vials, an insulin pen, and a researcher in the background.
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
By Thomas Hughes | September 23, 2026
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,186.95 +29.46 (+2.55%)
Closing price 03:58 PM Eastern
Extended Trading
$1,189.83 +2.88 (+0.24%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$38.20 +0.67 (+1.80%)
Closing price 03:58 PM Eastern
Extended Trading
$38.30 +0.10 (+0.26%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas